Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France

[1]  M. Payet,et al.  Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study. , 2018, Multiple sclerosis and related disorders.

[2]  T. Vos,et al.  Global, regional, and national incidence and prevalence, and years lived with disability for 328 diseases and injuries in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017 .

[3]  G. Comi,et al.  Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis , 2016, Expert opinion on drug safety.

[4]  M. Duddy,et al.  Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator , 2015, The Lancet Neurology.

[5]  S. Patten,et al.  Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study , 2015, PloS one.

[6]  A. Weill,et al.  Prévalence de la sclérose en plaques en France en 2012 et mortalité associée en 2013 à partir des données du Sniiram-PMSI , 2015 .

[7]  M. C. Amigo-Jorrín,et al.  Long-term effectiveness of glatiramer acetate in clinical practice conditions , 2014, Journal of Clinical Neuroscience.

[8]  Martin Duddy,et al.  UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model , 2014, BMJ Open.

[9]  J. Lechner-Scott,et al.  The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform , 2013, PloS one.

[10]  Marc Debouverie,et al.  Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture–recapture method , 2012, Multiple sclerosis.

[11]  S. Agarwal,et al.  Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis , 2011, Patient preference and adherence.

[12]  S. Vukusic,et al.  Geographic variations of multiple sclerosis in France. , 2010, Brain : a journal of neurology.

[13]  M. Reynolds,et al.  Persistence and adherence to disease modifying drugs among patients with multiple sclerosis , 2010, Current medical research and opinion.

[14]  Yinshan Zhao,et al.  Impact of multiple sclerosis relapses on progression diminishes with time , 2009, Neurology.

[15]  C. Pozzilli,et al.  Clinical markers of therapeutic response to disease modifying drugs , 2008, Neurological Sciences.

[16]  J. Wolinsky,et al.  A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients , 2006, Multiple sclerosis.

[17]  X. Montalban,et al.  Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.

[18]  X. Montalban,et al.  Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis , 2005, Multiple sclerosis.

[19]  X. Montalban,et al.  Interferon beta in relapsing–remitting multiple sclerosis , 2005, Journal of Neurology.

[20]  S. Vukusic,et al.  Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.

[21]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[22]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[23]  Syndrome de Turner.  GUIDE - AFFECTION DE LONGUE DURÉE , 2008 .

[24]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.